Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant700 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02302833 | Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05420636 | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | terminated | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT02769832 | Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer | completed | Phase 2 | 32 | Muhammad FurqanOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04579679 | Open-Label Surufatinib in European Patients With NET | terminated | Phase 2 | 78 | HutchmedINDUSTRY | 7 | Jul 25, 2025 | clinicaltrials |
| NCT02678780 | Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors(TALENT) | completed | Phase 2 | 123 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | Jul 24, 2025 | clinicaltrials |
| NCT04268121 | Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas(NEONEC) | recruiting | Phase 2 | 78 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04837885 | Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases(LUTARTERIAL) | recruiting | Phase 2 | 23 | University Hospital, BordeauxOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06395402 | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry(LUMOD-ID) | recruiting | Phase 2 | 120 | University of IowaOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076914 | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy(PPI-PROTECT) | not yet recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077564 | The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy(SKB264-II-NEN) | not yet recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Jul 22, 2025 | clinicaltrials |
| NCT07076095 | A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer | not yet recruiting | Phase 2 | 200 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Jul 21, 2025 | clinicaltrials |
| NCT03670056 | Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy | active not recruiting | Phase 2 | 25 | Yale UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07070011 | Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer | recruiting | — | 38 | Shanghai Chest Hospital of Shanghai Jiao Tong UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05173246 | JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma | recruiting | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC(SHARP) | recruiting | Phase 3 | 340 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07069270 | A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy | not yet recruiting | Phase 2 | 28 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 16, 2025 | clinicaltrials |
| NCT03335670 | Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 30 | Yusuf MendaOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT05111509 | A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent | active not recruiting | Early Phase 1 | 20 | Yusuf MendaOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07063407 | Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 1 | 50 | Shanghai Hansoh Biomedical Co., LtdINDUSTRY | 0 | Jul 14, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05224141 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) | active not recruiting | Phase 3 | 460 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Jul 8, 2025 | clinicaltrials |
| NCT05557708 | A Safety Study of 212Pb-Pentixather Radioligand Therapy | not yet recruiting | Early Phase 1 | 20 | Yusuf MendaOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03382561 | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 160 | National Cancer Institute (NCI)NIH | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07048964 | A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations | not yet recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05233878 | Prognostic's Factors of Head and Neck Paragangliomas Evolution(PRONO-PARAG) | active not recruiting | — | 25 | Hospices Civils de LyonOTHER | 1 | Jun 30, 2025 | clinicaltrials |
| NCT04400188 | A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06732505 | A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens | recruiting | Phase 1 | 36 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT03576040 | Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors(GAPET-NET) | completed | — | 120 | University Hospital, BrestOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT01673906 | 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours | completed | Phase 2 | 142 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 2 | Jun 24, 2025 | clinicaltrials |
| NCT05534594 | Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer(MIMETIC) | completed | N/A | 8 | University Medical Center GroningenOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05623319 | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)(THOR) | recruiting | Phase 2 | 60 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06826677 | REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER(ARAL) | completed | — | 71 | AstraZenecaINDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07034859 | Cabergoline in the Management of Nonfunctioning Pituitary Adenoma | enrolling by invitation | Phase 4 | 30 | National Taiwan University HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study(CABATEN) | completed | Phase 2 | 93 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06954246 | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 450 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07026669 | A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer | recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04952480 | Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer(DARTS) | recruiting | Phase 2 | 31 | AHS Cancer Control AlbertaOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05702944 | The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma | recruiting | Phase 4 | 24 | Seoul National University HospitalOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02324296 | PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases | completed | — | 46 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 0 | Jun 11, 2025 | clinicaltrials |
| NCT06043193 | Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.(AURA-RIV-TNE) | recruiting | — | 100 | Hospices Civils de LyonOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07014540 | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 4 | 45 | Beijing GoBroad HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03466216 | Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET | terminated | Phase 1 | 33 | Orano Med LLCINDUSTRY | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07012330 | Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients | terminated | Phase 2 | 111 | Erasmus Medical CenterOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT07014254 | Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies | not yet recruiting | N/A | 20 | Xijing HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jul 31, 2025source: clinicaltrials